HK1129601A1 - Compositions for contributing to the treatment of cancers - Google Patents

Compositions for contributing to the treatment of cancers

Info

Publication number
HK1129601A1
HK1129601A1 HK09109362.2A HK09109362A HK1129601A1 HK 1129601 A1 HK1129601 A1 HK 1129601A1 HK 09109362 A HK09109362 A HK 09109362A HK 1129601 A1 HK1129601 A1 HK 1129601A1
Authority
HK
Hong Kong
Prior art keywords
cancers
contributing
compositions
treatment
Prior art date
Application number
HK09109362.2A
Other languages
English (en)
Inventor
Anil Gulati
Guru Reddy
Luigi Lenaz
Original Assignee
Spectrum Pharmaceuticals Inc
Trustees Of The University Of Illinoi Board Of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc, Trustees Of The University Of Illinoi Board Of filed Critical Spectrum Pharmaceuticals Inc
Publication of HK1129601A1 publication Critical patent/HK1129601A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK09109362.2A 2006-08-02 2009-10-09 Compositions for contributing to the treatment of cancers HK1129601A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/461,961 US20070032422A1 (en) 2002-10-24 2006-08-02 Methods, compositions and articles of manufacture for contributing to the treatment of cancers
PCT/US2007/074036 WO2008016793A2 (en) 2006-08-02 2007-07-20 Methods, compositions and articles of manufacture for contributing to the treatment of cancers

Publications (1)

Publication Number Publication Date
HK1129601A1 true HK1129601A1 (en) 2009-12-04

Family

ID=38752363

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09109362.2A HK1129601A1 (en) 2006-08-02 2009-10-09 Compositions for contributing to the treatment of cancers

Country Status (18)

Country Link
US (4) US20070032422A1 (xx)
EP (2) EP2046323B1 (xx)
JP (1) JP2009545609A (xx)
KR (1) KR101507178B1 (xx)
CN (1) CN101522186B (xx)
AR (1) AR062177A1 (xx)
BR (1) BRPI0715521A2 (xx)
CA (1) CA2658340C (xx)
DK (1) DK2046323T3 (xx)
ES (1) ES2402232T3 (xx)
HK (1) HK1129601A1 (xx)
IL (1) IL196825A (xx)
MX (1) MX2009001233A (xx)
NO (1) NO20090915L (xx)
RU (1) RU2407527C2 (xx)
TW (1) TWI469776B (xx)
WO (1) WO2008016793A2 (xx)
ZA (1) ZA200900017B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
JP5306208B2 (ja) 2006-08-31 2013-10-02 スペクトラム ファーマシューティカルズ インコーポレイテッド エンドセリンアゴニストの投与による放射線療法への腫瘍細胞の感作
US8623823B2 (en) * 2007-08-21 2014-01-07 Midwestern University Methods for treatment of stroke or cerebrovascular accidents using an ETB receptor agonist
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
WO2017191843A1 (ja) * 2016-05-06 2017-11-09 一般財団法人バイオダイナミックス研究所 高分子化薬物含有医薬組成物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550110A (en) * 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
CA2135151A1 (en) 1993-11-08 1995-05-09 Mitsuhiro Wakimasu Cyclic hexapeptides, their production and use
US5811416A (en) * 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
CA2206119C (en) 1994-12-12 2008-05-13 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US6251861B1 (en) 1996-06-27 2001-06-26 Takeda Chemical Industries, Ltd. Treatment of cerebral infarction using cyclic hexapeptides
CA2268640A1 (en) 1998-04-14 1999-10-14 Mitsuru Shiraishi Composition for preventing or treating ischemic disease
DE69903458T2 (de) 1998-09-25 2003-07-10 Warner Lambert Co Chemotherapie des krebses mit acetyldinalin in verbindung mit gemcitabin, capecitabin oder cisplatin
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
BR0111207A (pt) 2000-05-31 2003-04-01 Warner Lambert Co Combinações de um antagonista receptor de endotelina e um composto antiepiléptico tendo propriedades de alìvio da dor ou analgésicos
WO2002049630A2 (en) * 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
WO2003009805A2 (en) 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US20030229004A1 (en) 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
US8217010B2 (en) * 2002-10-24 2012-07-10 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
US20040138121A1 (en) 2002-10-24 2004-07-15 Anil Gulati Method and composition for preventing and treating solid tumors
EP1819367B1 (en) 2004-11-22 2013-11-20 The Board Of Trustees Of The University Of Illinois Use of the endothelin etb receptor agonists irl-1620 in tumor imaging
CA2598439A1 (en) * 2005-02-22 2006-08-31 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
JP5306208B2 (ja) 2006-08-31 2013-10-02 スペクトラム ファーマシューティカルズ インコーポレイテッド エンドセリンアゴニストの投与による放射線療法への腫瘍細胞の感作

Also Published As

Publication number Publication date
IL196825A0 (en) 2011-08-01
KR20090034355A (ko) 2009-04-07
TWI469776B (zh) 2015-01-21
CN101522186A (zh) 2009-09-02
US20110315575A1 (en) 2011-12-29
US8030278B2 (en) 2011-10-04
DK2046323T3 (da) 2013-04-22
ZA200900017B (en) 2009-11-25
RU2009107085A (ru) 2010-09-10
IL196825A (en) 2015-08-31
MX2009001233A (es) 2009-02-12
US20090155206A1 (en) 2009-06-18
NO20090915L (no) 2009-02-27
US20130102543A1 (en) 2013-04-25
TW200820965A (en) 2008-05-16
WO2008016793A2 (en) 2008-02-07
US8440620B2 (en) 2013-05-14
WO2008016793A3 (en) 2008-07-31
JP2009545609A (ja) 2009-12-24
EP2450037A1 (en) 2012-05-09
ES2402232T3 (es) 2013-04-30
CA2658340C (en) 2015-11-24
US8729023B2 (en) 2014-05-20
KR101507178B1 (ko) 2015-03-30
CN101522186B (zh) 2013-06-05
AR062177A1 (es) 2008-10-22
CA2658340A1 (en) 2008-02-07
BRPI0715521A2 (pt) 2013-06-25
US20070032422A1 (en) 2007-02-08
EP2046323B1 (en) 2013-02-13
RU2407527C2 (ru) 2010-12-27
EP2046323A2 (en) 2009-04-15

Similar Documents

Publication Publication Date Title
HK1256861A1 (zh) 用於治療胃腸道炎症的組合物
IL248204A0 (en) Combined treatment of tumors expressing 38cd
EP1996612A4 (en) COMPOSITIONS FOR THE TREATMENT OF CANCER
GB0719161D0 (en) Improvements relating to fabrick treatment compositions
IL200090A0 (en) Composition for treatment of undifferentiated-type of gastric cancer
PL2119477T3 (pl) Kompozycja do leczenia kserostomii lub suchej jamy ustnej
IL243294A0 (en) Compounds and compositions for the treatment of cancer
IL199941A0 (en) Compositions of stable tiacumicins
IL197235A0 (en) Therapeutic compositions
IL238394B (en) Preparations containing a combination of factors for the treatment of cancer
GB0909297D0 (en) Composition for the treatment of skin conditions
HK1129601A1 (en) Compositions for contributing to the treatment of cancers
EP1979487A4 (en) COBALAMINE COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2174956A4 (en) COMPOSITIONS FOR ANTIFIBRINOLYSIS THERAPY
EP2061493A4 (en) COMPOSITIONS FOR REDUCING OR PREVENTING SKIN CANCER
PL2252302T3 (pl) Kompozycja do leczenia zapalenia kości i stawów
HU0500947D0 (en) Composition for treatment of paradontosis
HK1140145A1 (en) Compositions for contributing to the treatment of cancers
HUP0500948A2 (en) Composition for treatment of diabeticus paradontosis
IL184620A0 (en) Composition for the treatment of inflammation
GB0710144D0 (en) Therapeutic compositions
GB0722030D0 (en) Compositions for treating tumours
GB0705674D0 (en) Composition for the treatment of halitosis
IL210519A0 (en) Anti-phthiraptera treatment compositions